Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed

Read the latest report on Sunshine Biopharma here.

Protests have mounted in intensity across China in the past weeks, as more and more citizens become frustrated with the country’s radical “Zero-Covid” policies. This was part of the cause for the markets having a rocky opening last week, with Tesla, Inc. TSLA and Apple, Inc. AAPL stock falling and a widespread drop in the oil sector in response to the continuing instability. 

This uncertainty is a reminder that, even as some describe living with the virus as a ‘new normal,’ complacency toward Covid carries risks. Clearly, there is a need for more effective solutions. 

Sunshine Biopharma, Inc. SBFM is a Canada-based pharmaceutical company combating COVID-19 through the development of SBFM-PL4, an antiviral treatment. It believes this drug, which it anticipates could be taken in tablet form from home, could be the kill shot for COVID and could help finally put an end to the pandemic.

Partnering With The University of Arizona University For Covid Research

A fully integrated pharmaceutical company, Sunshine Biopharma specializes in the research and development (R&D) of oncological and antiviral treatments and has multiple ongoing development projects, including SBFM-PL4. The strong team at Sunshine recently started a collaboration with the University of Arizona. Led by Dr. Gregory Thatcher, the collaboration will continue research into SBFM-PL4, and involve testing PLpro inhibitors to see how the drug reacts with the immune system.

While companies like Pfizer PFE, Eli Lilly and Co. LLY, and Regeneron Pharmaceuticals Inc. REGN have developed treatments for COVID, concerns around these drugs range from their limited efficacy to questions around their safety and drug resistance. 

Meanwhile, Sunshine’s drug targets nsp3 protease, the enzyme which suppresses the patient’s immune system and allows the Covid virions to effect maximal damage.  As an nsp3 protease inhibitor, SBFM-PL4 doesn’t merely weaken the virus, like other treatments, but also supports overall health by allowing the patient’s immune system to fight back. The company is confident that, in a Covid-19 vaccine market worth $13.6 billion, its drug candidate could provide a welcome solution. 

“It is urgent that effective treatments and more specific vaccines be developed at an accelerated pace,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are delighted to be working with Dr. Gregory Thatcher, who is aiming to find a wide array of inhibitors for PLpro (also called nsp3), as this virus-encoded protease is responsible for the suppression of the human immune system.”

Along with this important collaboration, Sunshine Biopharma can reflect proudly on a year that saw the company report growth in its financial position and a recent acquisition that may help the company enter the generic prescription drug market and become profitable. It is also developing a drug – Adva-27a – which it believes will be successful in treating various forms of multidrug-resistant cancer. In addition, the company is developing a vaccine-like mRNA treatment for cancer.

Want to learn more about Sunshine Biopharma? Visit its website

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Featured photo from Iryna Rahalskaya by Shutterstock.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksGeneralPartner ContentSunshine Biopharma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!